Dennis Moorefield v. Enzymotec Ltd.; Wells Fargo Securities; Canaccord Genuity Inc.;

     Enzymotec achieved a $57.4 million IPO by concealing operations issues with its baby formula business in China, a class claims.

Exit mobile version